Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.12M | 5.14M | 3.39M | 3.06M | 3.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.09M | 8.77M | 7.03M | 5.87M | 6.23M |
| Operating Income | -9.09M | -8.77M | -7.03M | -5.87M | -6.23M |
| Income Before Tax | -9.10M | -8.77M | -7.04M | -5.88M | -6.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.10 | -8.77 | -7.04 | -5.88 | -6.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.10M | -8.77M | -7.04M | -5.88M | -6.24M |
| EBIT | -9.09M | -8.77M | -7.03M | -5.87M | -6.23M |
| EBITDA | -8.98M | -8.66M | -6.94M | -5.79M | -6.17M |
| EPS Basic | -2.27 | -2.88 | -4.46 | -5.63 | -8.80 |
| Normalized Basic EPS | -1.42 | -1.80 | -2.34 | -3.05 | -5.03 |
| EPS Diluted | -2.27 | -2.88 | -4.46 | -5.63 | -8.80 |
| Normalized Diluted EPS | -1.42 | -1.80 | -2.34 | -3.05 | -5.03 |
| Average Basic Shares Outstanding | 15.65M | 13.27M | 10.01M | 6.81M | 3.83M |
| Average Diluted Shares Outstanding | 15.65M | 13.27M | 10.01M | 6.81M | 3.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |